Releases
BEAM
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest BEAM THERAPEUTICS INC. (BEAM) stock and general news. This information may help you make smarter investment decisions.
About BEAM
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS). The Company has three development candidates, such as BEAM-101, BEAM-102 and BEAM-201 in which two candidates targeting hemoglobinopathies and one candidate in T-cell therapy program.